SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes

Janet M. Wenzlau, Ong Moua, Suparna A. Sarkar, Liping Yu, Marian Rewers, George S. Eisenbarth, Howard W. Davidson, John C. Hutton

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

90 Scopus citations

Abstract

Type 1A diabetes (T1D) results from autoimmunity targeted at a limited number of molecules that are expressed in the pancreatic β cell. Putative novel autoantigen candidates were identified from microarray expression profiling of human and rodent islet cells. The highest ranking candidate was Slc30A8 (zinc transporter 8; ZnT8), which was screened by radioimmunoprecipitation assays against new-onset T1D and prediabetic sera. Such assays detected 63% of subjects with new-onset diabetes, but fewer than 2% of controls, 3% of those with type 2 diabetes, and 10% of patients with other autoimmune disorders. ZnT8 autoantibodies were found, however, in 26% of T1D subjects previously classified as autoantibody-negative on the basis of existing markers (GADA, IA2 A, IAA, and ICA). We conclude that SLC30A8 provides an important additional and independent predictive marker for T1D.

Original languageEnglish
Title of host publicationImmunology of Diabetes V From Bench to Bedside
PublisherBlackwell Publishing Inc.
Pages256-259
Number of pages4
ISBN (Print)9781573317337
DOIs
StatePublished - Dec 2008
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
Volume1150
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Keywords

  • Autoantibodies
  • ICA
  • Zinc transporter

Fingerprint

Dive into the research topics of 'SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes'. Together they form a unique fingerprint.

Cite this